Real-World Clinical Outcomes After Sustained Delivery of the 0.19 mg Fluocinolone Acetonide Implant for Treatment of Diabetic Macular Edema
The fluocinolone acetonide implant demonstrated sustained visual stability, significant anatomical improvement, reduced treatment burden, and a manageable safety profile. These findings support its role as an effective long-term therapeutic option for DME, including in vitrectomized eyes.
Authors
- Joseph Coney (ORCID: https://orcid.org/0000-0002-6889-2637)
- Richard Donkor (ORCID: https://orcid.org/0000-0001-5669-5380)
- Damla Oncel
- Sarah Godel (ORCID: https://orcid.org/0009-0001-6101-441X)
Institutions
- University of Miami (US)
- Loyola University Chicago (US)
- Retina Associates (US)
- University of Missouri (US)
Publication Details
- Journal
- Journal of VitreoRetinal Diseases
- Published
- 2025-11-07
- DOI
- https://doi.org/10.1177/24741264251380717
- Citations
- 1
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.71